» Articles » PMID: 34454008

Calcineurin in the Heart: New Horizons for an Old Friend

Overview
Journal Cell Signal
Date 2021 Aug 28
PMID 34454008
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Calcineurin, also known as PP2B or PPP3, is a member of the PPP family of protein phosphatases that also includes PP1 and PP2A. Together these three phosphatases carryout the majority of dephosphorylation events in the heart. Calcineurin is distinct in that it is activated by the binding of calcium/calmodulin (Ca/CaM) and therefore acts as a node for integrating Ca signals with changes in phosphorylation, two fundamental intracellular signaling cascades. In the heart, calcineurin is primarily thought of in the context of pathological cardiac remodeling, acting through the Nuclear Factor of Activated T-cell (NFAT) family of transcription factors. However, calcineurin activity is also essential for normal heart development and homeostasis in the adult heart. Furthermore, it is clear that NFAT-driven changes in transcription are not the only relevant processes initiated by calcineurin in the setting of pathological remodeling. There is a growing appreciation for the diversity of calcineurin substrates that can impact cardiac function as well as the diversity of mechanisms for targeting calcineurin to specific sub-cellular domains in cardiomyocytes and other cardiac cell types. Here, we will review the basics of calcineurin structure, regulation, and function in the context of cardiac biology. Particular attention will be given to: the development of improved tools to identify and validate new calcineurin substrates; recent studies identifying new calcineurin isoforms with unique properties and targeting mechanisms; and the role of calcineurin in cardiac development and regeneration.

Citing Articles

Calcineurin-NFAT dynamics correspond to cardiac remodeling during aortic banding and debanding, mimicking aortic valve replacement.

Lunde I, Skrbic B, Sjaastad I, Christensen G, Carlson C, Tonnessen T Front Mol Med. 2024; 2:980717.

PMID: 39086965 PMC: 11285616. DOI: 10.3389/fmmed.2022.980717.


Combined Pharmacological Modulation of Translational and Transcriptional Activity Signaling Pathways as a Promising Therapeutic Approach in Children with Myocardial Changes.

Kamenshchyk A, Belenichev I, Oksenych V, Kamyshnyi O Biomolecules. 2024; 14(4).

PMID: 38672493 PMC: 11047929. DOI: 10.3390/biom14040477.


Inhibition of adenylyl cyclase 8 prevents the upregulation of Orai1 channel, which improves cardiac function after myocardial infarction.

Falcon D, Calderon-Sanchez E, Mayoral-Gonzalez I, Martin-Bornez M, Dominguez-Rodriguez A, Gutierrez-Carretero E Mol Ther. 2024; 32(3):646-662.

PMID: 38291755 PMC: 10928147. DOI: 10.1016/j.ymthe.2024.01.026.


RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic targeting.

Lymperopoulos A, Borges J, Stoicovy R Biochem Pharmacol. 2023; 218:115904.

PMID: 37922976 PMC: 10841918. DOI: 10.1016/j.bcp.2023.115904.


Hepatic ischemia-reperfusion syndrome and its effect on the cardiovascular system: The role of treprostinil, a synthetic prostacyclin analog.

Mouratidou C, Pavlidis E, Katsanos G, Kotoulas S, Mouloudi E, Tsoulfas G World J Gastrointest Surg. 2023; 15(9):1858-1870.

PMID: 37901735 PMC: 10600776. DOI: 10.4240/wjgs.v15.i9.1858.


References
1.
Li L, Li J, Drum B, Chen Y, Yin H, Guo X . Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve. Cardiovasc Res. 2016; 113(2):147-159. PMC: 5340143. DOI: 10.1093/cvr/cvw221. View

2.
Ni Y, Wang N, Cao D, Sachan N, Morris D, Gerard R . FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci U S A. 2007; 104(51):20517-22. PMC: 2154463. DOI: 10.1073/pnas.0610290104. View

3.
Sarparanta J, Blandin G, Charton K, Vihola A, Marchand S, Milic A . Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to tibial and limb-girdle muscular dystrophies. J Biol Chem. 2010; 285(39):30304-15. PMC: 2943315. DOI: 10.1074/jbc.M110.108720. View

4.
Shioda N, Han F, Moriguchi S, Fukunaga K . Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem. 2007; 102(5):1506-1517. DOI: 10.1111/j.1471-4159.2007.04600.x. View

5.
Ritter O, Hack S, Schuh K, Rothlein N, Perrot A, Osterziel K . Calcineurin in human heart hypertrophy. Circulation. 2002; 105(19):2265-9. DOI: 10.1161/01.cir.0000016044.19527.96. View